Fax: (313) 576-8628
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have free access to this content
Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers
Article first published online: 12 OCT 2012
DOI: 10.1002/cncr.27836
Copyright © 2012 American Cancer Society
Additional Information
How to Cite
Gray, J. E., Altiok, S., Alexandrow, M. G., Walsh, F. W., Chen, J., Schell, M. J., Tai, D. F. and Bepler, G. (2013), Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. Cancer, 119: 1023–1032. doi: 10.1002/cncr.27836
- †
Fax: (313) 576-8628
Publication History
- Issue published online: 19 FEB 2013
- Article first published online: 12 OCT 2012
- Manuscript Accepted: 9 AUG 2012
- Manuscript Revised: 2 AUG 2012
- Manuscript Received: 22 JUN 2012
REFERENCES
- 1World Health Organization (WHO). World Health Organization 2011 Cancer Fact Sheet. No. 297, February 2011. Geneva, Switzerland: WHO; 2011. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/index.html. Accessed September 26, 2011.
- 2, . Chemoprevention for lung cancer. Oncol Spectrums. 2002; 3: 116–126.
- 3, . Recent advances in chemoprevention of cancer. Science. 1997; 278: 1073–1077.
- 4, . Lung cancer chemoprevention. Semin Surg Oncol. 2000; 18: 100–105.
- 5
- 6, , , et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996; 334: 1145–1149.
- 7, , , et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996; 334: 1150–1155.
- 8, , , , . EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst. 2000; 92: 977–986.
- 9, , , et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001; 93: 605–618.
- 10, , , et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res. 2011; 4: 793–802.
- 11, , , et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected non-small cell lung carcinoma. Cancer. 2000; 89: 1457–1465.
- 12, , , et al. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol. 2001; 19: 4259–4266.
- 13. Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol. 1998; 31: 721–728.
- 14, . Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs. 1999; 17: 227–240.
- 15. Inhibition of protein kinase C—do we, can we, and should we? Pharmacol Ther. 1999; 82: 263–267.
- 16, , , et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 1982; 257: 7847–7851.
- 17, , , et al. Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J Biol Chem. 1983; 258: 11442–11445.
- 18, , . Characterization of a specific phorbol ester aporeceptor in mouse brain cytosol. Proc Natl Acad Sci U S A. 1983; 80: 4208–4212.
- 19, , , , , . Overexpression of protein kinase C beta-II induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol. 1999; 145: 699–711.
- 20, , , et al. Disruption of protein kinase C-eta results in impairment of wound healing and enhancement of tumor formation in mouse skin carcinogenesis. Cancer Res. 2003; 63: 2404–2408.
- 21, . Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007; 7: 281–294.
- 22, , , et al. The protein kinase C beta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005; 65: 7462–7469.
- 23, , , et al. MCM2—a promising marker for premalignant lesions of the lung: a cohort study [serial online]. BMC Cancer. 2001; 1: 6.
- 24, , , , , . DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007; 356: 800–808.
- 25, , , et al. Evaluation of enzastaurin, an oral, serine/threonine kinase inhibitor, as second- or third-line therapy of non-small cell lung cancer. J Clin Oncol. 2008; 26: 1135–1141.
- 26, , . Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002; 8: 1323–1327.
- 27, , , et al. Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. Br J Cancer. 2010; 103: 802–811.
- 28, , , et al. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010; 5: 369–375.
- 29, , , et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila). 2011; 4: 984–993.
- 30, , , et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila). 2010; 3: 148–159.
- 31. Assessing efficacy in early phase cancer prevention clinical trials: the case of Ki-67 in the lung. Cancer Prev Res. 2010; 3: 128–131.
- 32. Altered histology provides a positive clinical signal in the bronchial epithelium. Cancer Prev Res. 2011; 4: 775–778.